Dishman Carbogen Amcis Q2 Results 2026: Net loss ₹67 Cr
Q2 FY27 results statement: what the company reported on revenue, margins and capex.
- Revenue
- ₹507Cr
- −22.3% YoY
- −25.1% QoQ
- Net profit
- −₹67Cr
- Q2 FY26: ₹65 Cr
- Margin
- 9.1%
- −13.7 pp YoY
- +0.2 pp QoQ
Guidance rank: #82 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
Dishman Carbogen Amcis Ltd Q2 FY27 key numbers
- Revenue
- The standalone total income from operations (net) for the quarter was ₹83.59 crores, up from ₹60.30 crores in the same quarter last year, showing an increase of about 38.7% year-on-year.
As stated in Dishman Carbogen Amcis Ltd's Q2 FY27 results statement · published 14 Nov 2026. Reported figures, not investment advice.
Based on Dishman Carbogen Amcis Ltd's Q2 FY27 results statement. The company has not published an earnings-call transcript for this quarter, so figures here are what the results statement reports, not management guidance.
The short version
For the quarter ended September 30, 2026, the consolidated total income from operations (net) was ₹507.37 crores, compared to ₹652.65 crores in the same quarter of the previous year, representing a de. For the quarter ended September 30, 2026 (Standalone):.
From Dishman Carbogen Amcis Ltd's Q2 FY27 earnings-call transcript · updated 14 Nov 2026.
How did Dishman Carbogen Amcis' revenue grow in the September 2026 quarter?
- For the quarter ended September 30, 2026, the consolidated total income from operations (net) was ₹507.37 crores, compared to ₹652.65 crores in the same quarter of the previous year, representing a decrease of approximately 22.3% year-on-year (Page 3).
- The standalone total income from operations (net) for the quarter was ₹83.59 crores, up from ₹60.30 crores in the same quarter last year, showing an increase of about 38.7% year-on-year (Page 10).
- The presentation notes changes in utilization of funds and some abandoned fundraising plans.
What happened to Dishman Carbogen Amcis' margins in Q2 FY27?
For the quarter ended September 30, 2026 (Standalone):
Locked: what Dishman Carbogen Amcis Ltd said on margins
Also locked on this page: fundraising
Free account, 30 seconds. No card needed.
What capex is Dishman Carbogen Amcis planning?
- The proceeds from the issue of Secured Non-Convertible Debentures have been utilized for:
- Capital Expenditure including maintenance capital expenditure and reimbursement of past capex.
- Capital expenditure specifically for maintenance capex in existing manufacturing units based in Gujarat.
2 more points from Dishman Carbogen Amcis Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Is Dishman Carbogen Amcis raising money or cutting debt?
The company raised INR 15.00 Crores via private placement of Senior, Secured, Rated, Listed…
Locked: what Dishman Carbogen Amcis Ltd said on fundraising
Also locked on this page: margins
Free account, 30 seconds. No card needed.
How big is Dishman Carbogen Amcis' order book?
2 more points from Dishman Carbogen Amcis Ltd's call on order book
Create a free account to keep reading this call
Dishman Carbogen Amcis Ltd — Quarterly revenue & net profit
Dishman Carbogen Amcis Ltd Q2 FY27 results — key figures
| ₹ Cr | Q2 FY27 | Q2 FY26 | YoY | Q1 FY27 | QoQ |
|---|---|---|---|---|---|
| Revenue | 507 | 653 | -22.3% | 678 | -25.1% |
| Operating profit (EBITDA) | 46 | 149 | -69.1% | 60 | -23.5% |
| Operating margin | 9.1% | 22.8% | -13.7 pp | 8.9% | +0.2 pp |
| Profit before tax | -81 | 31 | -365.2% | -51 | — |
| Net profit (PAT) | -67 | 65 | -202.2% | -58 | — |
| EPS (₹) | -4.26 | 4.16 | -202.4% | -3.69 | — |
Source: Dishman Carbogen Amcis Ltd's results filing to NSE (consolidated), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹507 Cr, net loss ₹67 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →More Q2 FY27 results in Pharmaceuticals & Biotechnology
- Sun Pharmaceutical Industries Q2 FY27 results
- Divis Laboratories Q2 FY27 resultsCapex ₹1,638 Cr
- Torrent Pharmaceuticals Q2 FY27 results
- Laurus Labs Q2 FY27 results
- Zydus Lifesciences Q2 FY27 results
- Dr Reddy's Labs Q2 FY27 resultsCapex ₹186 Cr
- Cipla Q2 FY27 results
- Mankind Pharma Q2 FY27 results
All Q2 FY27 results | Pharmaceuticals & Biotechnology rankings
Continue your research
What Dishman Carbogen's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Orchid Pharma (Q2 FY27)
4,280.8 lakhs (~14.3% increase). Key results statement takeaways from Orchid Pharma Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
- Gujarat Themis Biosyn (Q2 FY27)
Standalone: ₹4,745.52 Lakhs . Key results statement takeaways from Gujarat Themis Biosyn Ltd's Q2 FY27 results statement — and how it ranks against sector peers
- Nectar Lifescience (Q2 FY27)
Quarterly EBITDA**: ₹52.7 crore, down 88% YoY . Key results statement takeaways from Nectar Lifescience Ltd's Q2 FY27 results statement — and how it ranks again
- Gufic BioScience (Q2 FY27)
288.4 crore, up from Rs. Key investor presentation takeaways from Gufic BioSciences Ltd's Q2 FY27 investor presentation — and how it ranks against sector peers.
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Dishman Carbogen Amcis Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Dishman Carbogen Amcis Ltd Q2 FY27 results?
For the quarter ended September 30, 2026, the consolidated total income from operations (net) was ₹507.37 crores, compared to ₹652.65 crores in the same quarter of the previous year, representing a de. For the quarter ended September 30, 2026 (Standalone):.
What is Dishman Carbogen Amcis Ltd share price analysis?
Dishman Carbogen Amcis Ltd currently shows a neutral. The stock trades at a P/E of 149.2 with a market cap of ₹2,707 Cr. Investors should review the full earnings analysis for detailed insights.
Is Dishman Carbogen Amcis Ltd planning capital expenditure?
The proceeds from the issue of Secured Non-Convertible Debentures have been utilized for:.
Keep Dishman Carbogen Amcis Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's results statement. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.